Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in reducing risk of cardiovascular disease, the most costly complication of type 2 diabetes. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was 'isolated' through comparison to diet, lifestyle or placebo. METHODS: We performed an electronic literature search of MEDLINE, EMBASE and the Cochrane Library. We also manually screened the reference lists of previous meta-analyses of trials of metformin identified through a MEDLINE search. We included randomised controlled trials of adults with type 2 diabetes comparing any dose and preparation of oral metformin with no intervention, placebo or a lifestyle intervention and reporting mortality or a cardiovascular outcome. RESULTS: We included ten articles reporting 13 trials (including a total of 2079 individuals with type 2 diabetes allocated to metformin and a similar number to comparison groups) of which only four compared metformin with placebo and collected data on cardiovascular outcomes. Participants were mainly white, aged ≤65 years, overweight/obese and with poor glycaemic control. Summary estimates were based on a small number of events: 416 myocardial infarctions/ischaemic heart disease events in seven studies and 111 strokes in four studies. The UK Prospective Diabetes Study (UKPDS) contributed the majority of data to the summary estimates, with weights ranging from 52.3% for myocardial infarction to 70.5% for stroke. All outcomes, with the exception of stroke, favoured metformin, with limited heterogeneity between studies, but none achieved statistical significance. Effect sizes (Mantel-Haenszel RR) were: all-cause mortality 0.96 (95% CI 0.84, 1.09); cardiovascular death 0.97 (95% CI 0.80, 1.16); myocardial infarction 0.89 (95% CI 0.75, 1.06); stroke 1.04 (95% CI 0.73, 1.48); and peripheral vascular disease 0.81 (95% CI 0.50, 1.31). CONCLUSIONS/INTERPRETATION: There remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in trials of metformin and a cardiovascular endpoint trial of metformin among people without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram [40]](https://figures.cochat.ai/paper-figures/21d83ef63bbb4a5890ce9f40e21450f3/impact-of-metformin-on-cardiovascular-disease-a-meta-analysis-of-randomised-figure-1.jpg)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In meta-analyses of 13 randomized clinical trials evaluating the CV effects of metformin vs. placebo or active control, including the data from the UKPDS, none of the differences in assessed CV outcomes was statistically significant.184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“12 weeks of treatment with licogliflozin led to a numerically greater reduction in liver lipid content, body weight (4.2 %) and HbA1c (1 %) compared to RCTs with sole SGLT2I treatment (Table 1) [161,163].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [163]
Experimental — accuracy not yet measuredIn the citing paper
“This Class IIa recommendation for metformin is based on the weight of opinion rather than the weight of evidence; results from meta-analyses of observational studies suggest associations with better CV outcome, but this is not supported by results from meta-analyses restricted to randomized trials in patients with T2DM and ASCVD, where no statistically significant effect of metformin has been”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
In the citing paper
“The pooled HRs (95% CIs) were: all-cause mortality 0.96 (0.84-1.09);CV death 0.97 ( 0.80-1.16); MI 0.89 (0.75-1.06); stroke 1.04 (0.73-1.48); and peripheral vascular disease 0.81 (0.50-1 31).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Metformin reduced the incidence of diabetes by 31% among people with glucose levels just below the diagnostic threshold in the US Diabetes Prevention Programme [36], and by 26% in the Indian equivalent [37].”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 10×
“studies [19, 21] to 15 years [27]) and poorly controlled diabetes (average baseline HbA1c was less than 8% [63.”
BackgroundMethodInfluentialLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“This contrasts with the evidence now available for newer and more expensive glucose-lowering drugs, such as empagliflozin [34] and liraglutide [10], and of course for medications targeting different risk factors, for example statins.”
Background
Cited by
Items 301–398 of 398
Janssen, J. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052150 · Cited by 2
“A recent meta-analysis on the impact of metformin on cardiovascular risk reduction in type 2 diabetes did not provide a clear picture and left its role in this respect undecided [120].”
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 34
[Metformin use and risk of ischemic stroke in patients with type 2 diabetes: A cohort study].
Yu, H., Yang, R. T., Wang, S. Y., Wu, J. H., Wang, M. Y., Qin, X. Y., Wu, T., Chen, D. F., Wu, Y., & Hu, Y. (2023) · PubMed Central · doi:10.19723/j.issn.1671-167x.2023.03.011 · Cited by 2
Scheen, A. J. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.04.014 · Cited by 2
Changing Fields-Diabetes Medications Invading the Cardiovascular Space
Breite, L. D., Steck, M., Cutshall, B. T., Shah, S. P., & Cave, B. E. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100736 · Cited by 4
Antoku, Y., Takemoto, M., Mito, T., Shiiyama, R., Otsuka-Morisaki, H., Tanaka, A., Maeda, Y., & Tsuchihashi, T. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6893-20 · Cited by 2
“Metformin (29) is a classical drug for T2DM that can reduce the risk of cardiovascular disease among patients with T2DM.”
BackgroundCardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Pietraszek, A. (2020) · Current Drug Safety · doi:10.2174/1574886315666200902154736 · Cited by 2
Nguyễn, N. C., Pham, H. T., Pham, D. T., Hoang, T. M. N., Dam, T. P. L., Ho, T. H., Dang, D. Q., Binh, N. T., & Huynh, Q. T. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.4672 · Cited by 3
Herzinsuffizienz bei Menschen mit Diabetes mellitus
Schütt, K. A. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00752-w · Cited by 2
“Auch in einer kürzlich durchgeführten Metaanalyse wurde kein klarer Effekt von Metformin auf kardiovaskuläre Endpunkte festgestellt [20].”
BackgroundThe unexpected benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors
Stewart, R., & Chan, C. (2022) · New Zealand Medical Journal · doi:10.26635/6965.5818 · Cited by 2
Metformin, Sulfonylureas, DPP-4 Inhibitors and Cardiovascular Outcomes in Type 2 DM
Scheen, A. J. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_32 · Cited by 2
Kp, Z., & Furmanova, O. V. (2018) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.14.2.2018.130564 · Cited by 3
“Как известно, с одной стороны, макрофаги являются мощными продуцентами провос палительных цитокинов, особенно ФНО-α [46], а с другой стороны — макрофаги участвуют в регуляции эндотелия сосудов, который значительно поражен у больных СД2, особенно осложненного атеросклерозом и коронарно-сосудистыми нарушениями [33, 64,…”
Tsabar, N., Press, Y., Rotman, J., Klein, B., Grossman, Y., Vainshtein‐Tal, M., & Eilat‐Tsanani, S. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.08.004 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00608-9 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Qarni, A. A. A., AlSubaiee, M., Husain, M., Alkhazmari, G., AlQahtani, A., Aldossary, I., Gado, W., Albahrani, Z., AlMukhaylid, S., Alarfaj, A., et al. (2023) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv5i2004 · Cited by 2
Grimaldi‐Bensouda, L., Bonnet, F., Hamon, Y., Touzé, E., & Abenhaim, L. (2024) · Thrombosis Update · doi:10.1016/j.tru.2024.100173 · Cited by 1
Chen, B., Tai, Y., Kong, Y., & Wang, C. (2025) · European journal of medical research · doi:10.1186/s40001-025-02878-9 · Cited by 2
“Previous research has established that metformin offers notable cardiovascular advantages for patients suffering from cardiovascular conditions, such as decreased rates of ACM and cardiovascular events [20, 21].”
Kim, H., Lee, S. W., Lim, Y., Han, N., Kang, S. H., Byun, Y., & Kim, K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333604 · Cited by 2
“Previous studies have shown that metformin, the first-line antidiabetic agent commonly used in combination with SGLT-2is in clinical practice, has no effect on CVD incidence [31,32].”
Heinzl, M. W., Resl, M., Maier, J., Steinwender, C., Falkensammer, J., Fellinger, P., Steinmaurer, T., Saely, C. H., Hoppichler, F., Stingl, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02667-8 · Cited by 1
“Auch Meta-analysen konnten einen kardiovaskulären Nutzen von Metformin feststellen, wobei hier Unterschiede ab-hängig vom jeweiligen Patientenkollektiv und den verwendeten Kontrollsubstanzen bestehen [80, 82–84].”
Al-Dhahi, A. S., Al‐kuraishy, H. M., Fawzy, M. N., & Batiha, G. E. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111925 · Cited by 1
Nonglycemic Outcomes of Antidiabetic Medications
Morse, C., Sze, D., Patel, D. K., & Goldman, J. D. (2018) · Clinical Diabetes · doi:10.2337/cd18-0015 · Cited by 1
“In this case, metformin showed no significant effect on risk of CV death, MI, or stroke (12).”
BackgroundEvaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
Paldánius, P. M. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0179 · Cited by 2
“The latest revisions of the guidelines already indicated that eventually UKPDS is the only study which has demonstrated signs of CV risk reduction with metformin while all the other evidence indicates presence of a summarised, neutral effect [124].”
BackgroundWidyatmaka, M. N., & Ismail, A. (2021) · Sains Medika Jurnal Kedokteran dan Kesehatan · doi:10.30659/sainsmed.v11i2.7656 · Cited by 2
“…multifunctional activity such as anti-oxidant, anti-cancer, cardiovascular protective, and anti-inflammatory (Saisho, 2015; Cameron et al., 2016; Griffin et al., 2017; HeckmanStoddard et al., 2017; Rena et al. , 2017) Metformin also manage to ameliorates insulitis condition in diabetic mice…”
BackgroundKim, S. S., & Kim, I. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_9 · Cited by 1
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
Talha, K. M., Fonarow, G. C., Virani, S. S., & Butler, J. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1155 · Cited by 1
The Effects and Treatment of Inflammation on Diabetes Mellitus and Cardiovascular Disease
Hattar, L., Mumtaz, T., Mouhayyar, C. E., Matevossian, A., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_10 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
“In einer kürzlichen Metaanalyse wurden weder signifikante positive noch negative Effekte von Metformin auf kardiovaskuläre Endpunkte gefunden [36]; allerdings räumen die Autoren ein, dass auch für die Metaanalyse die Zahlen zu gering sind und eine große kontrollierte Studie nötig wäre, um die Frage zu klären.”
Li, K., Liu, P., Ye, J., Liu, M., & Zhu, L. (2024) · Aging · doi:10.18632/aging.205775 · Cited by 4
Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
Avogaro, A. (2018) · Diabetes Mellitus · doi:10.14341/dm9816 · Cited by 1
Reprint of: Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention
Schwarz, P. E. H., Timpel, P., Harst, L., Greaves, C. J., Ali, M. K., Lambert, J. D., Weber, M. B., Almedawar, M. M., & Morawietz, H. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.026 · Cited by 2
Ten things you should know about type 2 diabetes – Part 1
Morris, D. (2019) · Independent Nurse · doi:10.12968/indn.2019.3.23 · Cited by 1
Oral Hypoglycemics in Patients with Type 2 Diabetes and Peripheral Artery Disease
Rannelli, L., Kaplovitch, E., & Anand, S. S. (2019) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v14i2.282 · Cited by 1
Burton, J. K., Quinn, T. J., & Fisher, M. (2019) · Practical Diabetes · doi:10.1002/pdi.2230 · Cited by 2
Prevention of type 2 diabetes in patients with chronic heart failure
Павликова, Е. П., Sorokina, A. G., & Potapenko, A. V. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-1-67-74 · Cited by 1
“сосудистых заболеваний на фоне приема метформина у пациентов без диабета так и оставался без ответа [19].”
Common Risk Factors and Prevention
Brainin, M., Teuschl, Y., & Matz, K. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108659574.008 · Cited by 1
SGLT2 Inhibitors and the Associated Risk of Genito Mycotic Infections – A Narrative Review
Sharanya Shre, E. S. (2022) · International Journal of Current Science Research and Review · doi:10.47191/ijcsrr/v5-i5-13
Ali, A., Pasha, A. T., & Malik, S. (2022) · International Journal of Multidisciplinary Sciences and Arts · doi:10.47709/ijmdsa.v1i1.1804 · Cited by 1
Role of supplementation in insulin resistance
Zmuda, E. J., & Glibowski, P. (2023) · Medycyna Ogólna i Nauki o Zdrowiu · doi:10.26444/monz/170821 · Cited by 1
Bajaj, N. S., & Vaduganathan, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1856 · Cited by 2
Wu, S., Dong, J., Sun, Y., Gao, J. P., Tian, R., & Yu, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-1743720/v1 · Cited by 1
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_19-1
Metformin: Pharmacogenetics and metabolic effects
Out (2018) · Research Publications (Maastricht University) · doi:10.26481/dis.20180709mo
Acyl-ghrelin mediated lipid retention and inflammation within in vitro and ex vivo adipose depots
Churm, R. (2018) · Cronfa (Swansea University) · doi:10.23889/suthesis.40925
Oral Glucose-Lowering Agents for the Treatment of Type 2 Diabetes Mellitus
Goh, S. (2019) · The Singapore Family Physician · doi:10.33591/45.1.u1
Cardiovascular primary prevention – directed approach for individual features
Mano, T. B., Rosa, S. A., Rio, P., Timóteo, A. T., & Ferreira, R. C. (2019) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2019.07.022
Buhse, S., & Mühlhauser, I. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_32
Deed, G., Atherton, J. J., dʼEmden, M. C., Rasalam, R. R., Sharma, A. K., & Sindone, A. P. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0663-x · Cited by 1
Die neue individuelle antihyperglykämische Therapie bei Typ-2-Diabetes
Konz, K. (2019) · Info Diabetologie · doi:10.1007/s15034-019-1561-z
Actual aspects in the primary prevention of cardiovascular diseases
Piloff, L. (2019) · Medic ro · doi:10.26416/med.131.3.2019.2585
Gorb, Y. G., Strona, V. I., & Komir, I. (2020) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs05.02.018
“Використання інсуліну та препаратів сульфонілсечовини можливо тільки за умов наявності прямих показань щодо лікування ЦД 2 типу, оскільки доказів їхнього благоприємного впливу на ризик розвитку ХСН не отримано [57, 79].”
Mohan, M. (2019) · Discovery Research Portal (University of Dundee)
Orale Antidiabetika bei Typ-2-Diabetes
Negrean, M. (2020) · Info Diabetologie · doi:10.1007/s15034-020-2209-8
Treatment of Metformin Decreases the Risk of Varicose Vein: A Mendelian Randomization StudyPreprint
Chen, Q., Li, L., Wu, R., Wang, S., & Yao, C. (2020) · Research Square · doi:10.21203/rs.3.rs-71387/v1
How effective is metformin in reducing cardiovascular risks in adults with T2DM?
Ahsani, N., & Williams, A. P. (2021) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001242
Building therapy in type 2 diabetes – metformin and beyond
Morris, D. (2021) · Independent Nurse · doi:10.12968/indn.2021.3.14
Perspektiven präventiver Therapie wider Schlaganfall und Demenz
Jander, S. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3686-0
Cobo, A. L., Masson, W. M., Lobo, M., Masson, G., & Molinero, G. B. (2021) · Research Square · doi:10.21203/rs.3.rs-664920/v1
Metformina: ¿Debería ser la primera opción terapéutica en el paciente con diabetes de alto riesgo?
Sanabria, H. D., & Cobo, A. L. (2021) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v88.i1.19784
Carrasco-Sánchez, F. J., Fern�ndez-Rodr�guez, J. M., Escribano, P. P. C., Miramontes-Gonz�lez, J. P., G�mez-Huelgas, R., Garc�a-de-Lucas, M. D., Ena, J., & Carretero-G�mez, J. (2021) · Spanish Journal of Medicine · doi:10.24875/sjmed.21000010
Stehouwer, C. D. A. (2021) · EMJ Diabetes · doi:10.33590/emjdiabet/21-00191
Pakaya, D., Demen, L. C. I., Harun, H., Anwar, S., & Lintin, G. B. R. (2022) · Mutiara Medika: Jurnal Kedokteran dan Kesehatan · doi:10.18196/mmjkk.v22i1.13358
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00765-5
Bianchi, C., Daniele, G., Dardano, A., & Prato, S. D. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_19
Lee, Y., Park, B., Hong, K., & Jung, D. (2021) · Research Square · doi:10.21203/rs.3.rs-295839/v1
Rizvi, A. A. (2021) · Journal of Modern Medicinal Chemistry · doi:10.12970/2308-8044.2021.09.03
“There is controversy regarding its role in preventing cardiovascular disease (CVD) [5].”
BackgroundStrategies for the Management of Type 2 Diabetes
Winocour, P. H., & Zac‐Varghese, S. (2022) · doi:10.1093/med/9780198870197.003.0259
Metformin in the prevention of colorectal cancer with diabetes mellitus
Друк, И. В., Lyalyukova, E. A., & Fadeeva, E. A. (2022) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-205-9-161-170
Behandlung von Diabetespatienten nach Schlaganfall
Jander, S. (2022) · Info Diabetologie · doi:10.1007/s15034-022-4444-7
Aluefua, O. F., Chika, A., Ishaka, A., & Abubakar, K. (2022) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_333_2022
Akhtar, F., Hamid, S., Abbas, A., Ehsan, S., Salam, R. A., & Anwer, K. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs20221612487
Editorial: New mechanisms and drugs for the treatment of cardiovascular disease with diabetes
Zhang, S., Li, J., Huang, Y., Yu, J., & Pan, X. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1144858
Su, J., Zhou, L., Yang, N., Xu, Y., Wang, G., & Liu, J. (2023) · Research Square · doi:10.21203/rs.3.rs-2849094/v1
Lehrke, M. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01034-3
Mühlhauser, I., Buhse, S., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_34
Vitamin B12 Deficiency in Relation to Metformin Use in Adults with Type-2 Diabetes Mellitus
Gul, A., Siddiqi, F. A., Amir, M., Arshad, A. R., Qayyum, S., & Shakireen, N. (2023) · Life and Science · doi:10.37185/lns.1.1.271 · Cited by 1
How to Use Type 2 Diabetes Treatments in Clinical Practice
Karagiannis, T., Liakos, A., & Τσάπας, Α. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch37
Hosoki, M., Hori, T., Kaneko, Y., Mori, K., Yasui, S., Tsuji, S., Yamagami, H., Kawata, S., Hara, T., Masuda, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051283
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Figshare · doi:10.6084/m9.figshare.20438489
Cardiovascular Disease Risk and Risk Reduction Strategies in Diabetes Mellitus
Wilson, D. P., Hamilton, L., & Maki, K. C. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_14
Liu, Z., Chen, X., Zhao, H.-Y., Zhan, S., & Sun, F. (2024) · PubMed Central · doi:10.19723/j.issn.1671-167x.2024.03.008 · Cited by 1
Paradigm shift in diabetes care: Glucose-centric to cardio-metabolicrenal approach
Rameshkumar, T., & Katulanda, P. (2022) · Ceylon Journal of Medical Science · doi:10.4038/cjms.v59i1.5065
“Meta-analysis of 13 trials involving 2079 patients comparing metformin with other medicines or placebo showed no statistically significant superiority in reducing the risk of all-cause mortality, cardiovascular death, myocardial infarction, stroke and peripheral vascular disease [10].”
MethodWarren, S., McKee, S., & Yakiwchuk, E. (2024) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.350
Pharmacological Interventions of Metabolic Syndrome
Mehta, A. A., Beladiya, J., & Gandhi, T. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-75686-3_22 · Cited by 2
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch03
Papel de la metformina en los tiempos del paciente cardiorrenometabólico
Arranz-Martínez, E., Hernández-Teixidó, C., & García, A. R. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102530 · Cited by 1
Lewis, C. R. (2025) · Jordan Journal of Pharmaceutical Sciences · doi:10.35516/jjps.v18i2.2313
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferović, P. M., & Wanner, C. (2022) · Figshare · doi:10.6084/m9.figshare.20438492
Li, T., Providencia, R. A., Mu, N., Yin, Y., Chen, M., Wang, Y., Liu, M., Yu, L., Gu, C., & Ma, H. (2021) · Figshare · doi:10.6084/m9.figshare.13669618
Kim, S. M., Shin, W., Yang, A., Kim, A., Lee, Y.-S., Na, J., Cho, J. M., Yoon, S., & Yoo, H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-04986-7
Yahia, O. A., Elzeiny, D. A., Elshenawy, D. S. A., Elsukary, A. E., Abdel-Halim, N. H. M., Elsherbini, S., & Hassan, Y. F. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124470
Abdel-Sadek, D. N., Abd-Elazez, T. M., & El-Haggar, S. M. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02255-w
“…have been successfully repurposed across diverse diseases; for example, metformin, initially approved for type 2 diabetes, has been explored in cancer (Brown et al. 2020), cardiovascular disease (Griffin et al. 2017), polycystic ovary syndrome (Bridger et al. 2006), and autoimmune disorders.”
Chan, A. H. Y., Beyene, K. A., Lai, B., Kim, S., Wu, I., Al-Jawadi, R., Wu, M., Foot, H., Cheung, G., Walker, X. J., et al. (2026) · Rejuvenation Research · doi:10.1177/15491684261462413
Mohammadi, D., Sadeghirad, B., Rasouli, M. A., Saed, L., Baradaran, H. R., & Moradi, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02226-9
Ahmed, S., McCollin, S. P., Martí-Carvajal, A. J., Akus, M., Baron, D. W., Razzaq, S. A., Scudder, P. N., Honigsberg, E. J., Nasir, S., Peng, K., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016380
Potential effects of metformin on psoriasis management: evidence from cells to bedside
Rutnumnoi, T., Chattipakorn, N., & Chattipakorn, S. C. (2026) · Archives of Dermatological Research · doi:10.1007/s00403-026-04822-1
Metadata
- Authors
- Griffin, S. J., Leaver, J. K., & Irving, G. J.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Griffin, Simon J.
- Venue
- Diabetologia
- Published
- 2017-08-02
- Volume
- 60
- Issue
- 9
- Pages
- 1620-1629
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC5552849
- OpenAlex
- W2740802742
- Cited by
- 398
- References
- 45
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 33 · 2023: 31 · 2022: 52 · 2021: 60 · 2020: 75 · 2019: 64 · 2018: 39 · 2017: 8
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Edge Hill University Research Information Repository (Edge Hill University) (publishedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- University of Cambridge
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, type 2 diabetes, cardiovascular disease, myocardial infarction, stroke, all-cause mortality, cardiovascular mortality, peripheral vascular disease, ischemic heart disease, UK Prospective Diabetes Study, lifestyle intervention, drug effectiveness, cardiovascular risk reduction, glycemic control, randomized controlled trials, meta-analysis of trials, study heterogeneity, publication bias
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.